Cheap antioxidant could replace costly drugs for Post-Transplant blood disorder
NCT ID NCT07279610
First seen Dec 16, 2025 · Last updated May 13, 2026 · Updated 20 times
Summary
This study tests whether N-acetylcysteine (NAC), a common antioxidant, can treat a severe blood clotting condition called TA-TMA that can happen after a stem cell transplant. About 44 adults who develop TA-TMA will receive NAC to see if it improves blood counts and organ function. Current treatments are either ineffective or very expensive, so NAC could offer a safe and affordable option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, China
Conditions
Explore the condition pages connected to this study.